At a Glance
- Company: BioMarin Pharmaceutical
- Focus area: Rare genetic disease, ENPP1 deficiency
- Trial result: Missed one of two main goals in Phase 3
- Population: Children aged 1 to 12
- Next steps: Company to provide further update on the programme
What happened?
BioMarin reported mixed Phase 3 results for its experimental therapy in children with ENPP1 deficiency, meeting one of the study’s two main goals but failing the other. The company has now taken another hit in its rare-disease portfolio after a series of setbacks in recent years.
Why does it matter?
The result is important because BioMarin has long relied on rare-disease assets to drive growth, and late-stage failures can slow that strategy materially. Even when a programme shows partial success, missing a primary endpoint can make approval and commercial planning much harder.
Who’s behind it?
BioMarin Pharmaceutical is the developer of the programme and one of the best-known rare-disease biotech companies. The update centres on its experimental enzyme therapy for ENPP1 deficiency, a serious inherited condition.
How was it achieved?
The therapy was tested in a late-stage study in children aged 1 to 12 with ENPP1 deficiency. BioMarin said the trial met one efficacy measure but not the other, suggesting the data package was not strong enough for a clear win.
What’s next?
BioMarin is expected to review the data and decide how to proceed with the programme. The company may need additional analysis, follow-up or a different development strategy before the asset can move forward.